ACET: adicetbio.com Company Value to Net Income

Adicet - graphic logo of issuer ACET

This ACET trading chart with the -0.30 indicator highlights the business protection provided by cell therapy patents and strict FDA regulations. Adicet Bio aims for expansion within the oncology and autoimmune pathology treatment segments. The firm's success relies on clinical test efficacy, biomanufacturing scalability, and the approval of final research stages.

adicetbio.com (ACET) Price to Earnings Ratio: for the period 07/04/2022 - 11/10/2026

Analytical breakdowns for Adicet Bio Inc. (ACET)

- price and consensus price forecast:
Stock Price Adicet|ACET - Consensus Target
- market capitalization information:
Market Value Adicet Bio, Inc.|ACET - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Share Adicet Bio|ACET - Company Book Value|Market Cap to Net Assets Ratio adicetbio.com|ACET - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Adicet Bio|ACET - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Adicet|ACET - Company Debts|Debt to Book Value Ratio Adicet Bio, Inc.|ACET - Company Long-Term Debts|Short-Term Debt Adicet Bio|Quick Ratio adicetbio.com
- earnings and market multiples details:
ACET - Net Profit|Net Profit Forecast Adicet Bio|ACET - P/E Multiple|Market Cap to Projected Earnings Adicet|ACET - PEG Multiple|Enterprise Value to EBITDA Ratio Adicet Bio, Inc.|ACET - Operating profit EBITDA|Net earnings per one share for the last twelve months Adicet Bio|ACET - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months adicetbio.com|ACET - Net earnings per share growth this year|Expected earnings per share trend next year Adicet Bio
Comprehensive company analysis:adicetbio.com ACET
Signature product of Adicet Bio Inc.

Fundamental asset selection requires analyzing the return on capital via the ratio of market capitalization to net income. This coefficient determines the investment payback period, which is critical for Adicet Bio (ACET) due to the high costs of FDA-certified manufacturing and unique T-cell therapy; consequently, the company's historical average P/E allows for the determination of the business's fair value and prevents overpaying at the peak of market expectations.

Key competitors

P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|AbCellera Bio - P/E Multiple|TRML - P/E Multiple|PGEN: P/E Multiple|Price to Earnings Multiple PHAR|NKTR (Nektar Therapeutics Inc.) - P/E Multiple|Upstream Bio, Inc. (UPB) - Business Payback Period|P/E Multiple ZBIO|Price to Earnings Ratio Immunome Bio IMNM|P/E Multiple GOSS (Gossamer Bio, Inc.)|kalvista.com (KALV) - Market Cap to Earnings|SEPN: Price to Earnings Ratio|Pieris Pharma - Market Price to Net Income Ratio|SVRA (Savara Corp) - Price to Earnings Ratio|Rigel Corp - Company Value to Net Income|ANAB (AnaptysBio, Inc.) - P/E Multiple|Price to Earnings Ratio ATXS|P/E Multiple ENGN|Business Payback Period RAPT Therapeutics Inc.|Price to Earnings Ratio Aerovate Therapeutics JBIO|Aclaris Therapeutics, Inc (ACRS) - Market Cap to Earnings|Kyverna Therapeutics - P/E Multiple|TLSA - P/E Multiple|CABA: P/E Multiple|Price to Earnings Ratio Ventyx Biosciences Inc.|THTX (Theratechnologies Inc) - P/E Multiple|Market Cap to Earnings Avalo Therapeutics Inc AVTX|Price to Earnings Ratio ELDN (Eledon Pharmaceuticals)|Market Price to Net Income Ratio AGEN|Price to Earnings Ratio Climb Bio CLYM|ZURA (Zura Bio Ltd) - Market Cap to Net Income|aTyr - P/E Multiple|Company Value to Net Income ADAG (Adagene)|IMA: P/E Multiple|Shattuck Labs (STTK) - P/E Multiple|Price to Earnings Ratio Equillium Inc|CNTB: Company Value to Net Income|Price to Earnings Ratio Immunic, Inc. (IMUX)|Price to Earnings Ratio atarabio.com ATRA|P/E Multiple IFRX (InflaRx)|P/E Multiple x4pharma.com XFOR|CELU: Price to Earnings Ratio|Company Value to Net Income INMB (INmune Bio Inc)|BRNS: P/E Multiple|KZR - Business Payback Period|Price to Earnings Ratio SAB Biotherapeutics|Price to Earnings Ratio akaritx.com (AKTX)|Price to Earnings Ratio Enlivex Therapeutics (ENLV)|Price to Earnings Ratio q32bio.com QTTB|GeoVax Labs Inc - Price to Earnings Ratio|P/E Multiple Edesa Biotech Corp EDSA|IBIO - Price to Earnings Ratio|CARM (Carisma Therapeutics) - Price to Earnings Multiple|XTLB: P/E Multiple|Market Cap to Earnings Bolt Biotherapeutics, Inc. (BOLT)|HCWB (HCW Biologics, Inc.) - P/E Multiple|P/E Multiple Aptevo|P/E Multiple AIM|aditxt.com - Price to Earnings Multiple|P/E Multiple GRI (GRI Bio)|Business Payback Period XORTX Therapeutics Inc (XRTX)|ReShape Lifesciences - P/E Multiple|Revelation Biosciences Corp (REVB) - Price to Earnings Ratio|INDP: P/E Multiple|Market Cap to Earnings scinai.com (SCNI)|Price to Earnings Ratio CALI|AFMD (Affimed Therapeutics) - Market Price to Net Income Ratio|Price to Earnings Ratio ALLK (Allakos Inc.)|HOOK (hookipapharma.com) - Company Value to Net Income|P/E Multiple IGMS (IGM Biosciences)|iteostherapeutics.com - Price to Earnings Ratio|Ocean Biomedical - P/E Multiple|Business Payback Period TC BioPharm (Holdings) Plc TCBP|Third Harmonic Bio, Inc (THRD) - Price to Earnings Ratio